Keros Therapeutics (NASDAQ:KROS) Trading Up 7.5%

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) shot up 7.5% during mid-day trading on Friday . The company traded as high as $61.92 and last traded at $61.41. 93,008 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 404,823 shares. The stock had previously closed at $57.10.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on KROS. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 27th. William Blair restated an "outperform" rating on shares of Keros Therapeutics in a research report on Wednesday, February 21st. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Friday, March 1st. Truist Financial restated a "buy" rating and issued a $100.00 price target on shares of Keros Therapeutics in a research report on Wednesday, March 13th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $86.00 price target on shares of Keros Therapeutics in a report on Thursday, February 29th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics has a consensus rating of "Buy" and an average target price of $86.00.

Keros Therapeutics Stock Performance

The stock has a 50-day simple moving average of $63.36 and a 200 day simple moving average of $48.64. The stock has a market capitalization of $2.18 billion, a P/E ratio of -11.65 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Friday, March 1st. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $0.14 million for the quarter. During the same period in the previous year, the company earned ($1.09) earnings per share. Equities analysts predict that Keros Therapeutics, Inc. will post -5.11 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Keros Therapeutics by 18.8% in the third quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company's stock worth $44,837,000 after acquiring an additional 222,652 shares in the last quarter. Braidwell LP increased its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Braidwell LP now owns 1,357,309 shares of the company's stock worth $43,271,000 after purchasing an additional 213,444 shares during the last quarter. Franklin Resources Inc. increased its holdings in Keros Therapeutics by 47.9% during the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company's stock worth $27,809,000 after buying an additional 226,674 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Keros Therapeutics during the fourth quarter worth $27,367,000. Finally, CHI Advisors LLC increased its stake in shares of Keros Therapeutics by 1.4% during the 3rd quarter. CHI Advisors LLC now owns 407,633 shares of the company's stock worth $12,995,000 after purchasing an additional 5,515 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.